Categories: COVID-19News

Bioxytran Interview at the Emerging Growth Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare
  • Wednesday, May 3, 2023 12:35 pm1:05 pm EST
  • Medical/Scientific Community Reaction to Peer Reviewed Article

BOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that Bioxtran CCO Michael Sheikh will be discussing the medical and scientific communities’ reaction to the latest peer reviewed journal article on the Emerging Growth Conference on May 3, 2023 at 12:35 pm EST. Investors are encouraged to preregister to ensure you are able to attend the conference and receive any updates that are released. Please submit your questions in advance to Questions@EmergingGrowth.com.

Event: Emerging Growth Conference
Date: May 3, 2023
Registration: https://goto.webcasts.com/starthere.jsp?ei=1603276&tp_key=0949b0f751&sti=bixt
Time: 12:35 pm – 1:05 pm EST

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and we will also release a link to that after the event.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Bioxytran, Inc.

Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, ProLectin-M, is a new class of antiviral drug designed to antagonize galectins in Covid-19, influenza, and respiratory syncytial virus (RSV). ProLectin-I is also a galectin antagonist to target idiopathic pulmonary fibrosis and Long Covid. BXT-25 is an acellular oxygen carrier (AOC) designed to deliver oxygen to hypoxic tissues. Bioxytran’s other development programs are for ischemia of the heart and stroke treatment. More information can be found at www.bioxytraninc.com

Investor Relations
Michael Sheikh
509-991-0245

mike.sheikh@bioxytraninc.com

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

Staff

Recent Posts

hūmānus and ARSPHR Launch Groundbreaking Rohingya Atrocities Archive, Continuing Mohibullah’s Sacrificial Fight for Truth and Justice

"If I die, it's okay. I will give my life for my community." Mohibullah LONDON, July…

8 minutes ago

Seegene unveils the world’s first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025

Fully Unmanned— CURECA™, the 100% Automated Diagnostic System Defining the Future Gold Standard, Debuts in Chicago,…

8 minutes ago

Nutex Health Responds to Short Seller Report

HOUSTON, July 23, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:…

6 hours ago

Happy Docs Make Happy Patients

AI technology boosts face-to-face time with patients, earns Mercy national recognition for physician satisfaction ST.…

6 hours ago

Waystar to Acquire Iodine Software, Accelerating the AI-Powered Transformation of Healthcare Payments

Extends Waystar's AI leadership into clinical intelligence software, unlocking greater value for clients and shareholders Highly…

12 hours ago

HAMILTON BEACH BRANDS HOLDING COMPANY ANNOUNCES DATES OF ITS 2025 SECOND QUARTER EARNINGS RELEASE AND CONFERENCE CALL

GLEN ALLEN, Va., July 23, 2025 /PRNewswire/ -- Hamilton Beach Brands Holding Company (NYSE: HBB)…

12 hours ago